Core Viewpoint - Huason Pharmaceutical (002907) announced that its crizotinib capsules are currently under patent protection by the original research company and are expected to be available for sale by the end of next year [1] Company Summary - The sales of the drug are influenced by various industry policies, and the company is currently unable to estimate the sales revenue [1]

Core Viewpoint - Huason Pharmaceutical has received the drug registration certificate for its product Crizotinib capsules from the National Medical Products Administration [1] Group 1 - The announcement was made on the evening of October 20 [1] - The approval signifies a regulatory milestone for Huason Pharmaceutical in bringing Crizotinib to market [1]

Core Viewpoint - Huason Pharmaceutical has received the drug registration certificate for Crizotinib capsules from the National Medical Products Administration, marking a significant milestone in its oncology product portfolio [1] Group 1: Company Developments - The approval of Crizotinib capsules allows Huason Pharmaceutical to treat ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients, as well as ROS1-positive advanced NSCLC patients [1] - Huason Pharmaceutical becomes the second company in the country to obtain approval for this product, filling a gap in its oncology offerings [1] - The introduction of this drug is expected to enhance the company's brand influence in the oncology segment [1]

Core Viewpoint - The company received approval from the National Medical Products Administration for its product, Crizotinib capsules, which has been in the Chinese market since 2013 and included in medical insurance since 2018, demonstrating over ten years of clinical application experience [1] Company Summary - Crizotinib capsules are primarily used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are positive for anaplastic lymphoma kinase (ALK) and for patients with advanced NSCLC who are positive for ROS1 [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its product, Crizotinib capsules, which has been in the Chinese market since 2013 and included in medical insurance since 2018, demonstrating over ten years of clinical application experience [1] Group 1 - Crizotinib capsules are primarily used for treating locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are positive for anaplastic lymphoma kinase (ALK) and for those with advanced NSCLC who are positive for ROS1 [1]

Core Viewpoint - Huason Pharmaceutical (002907.SZ) has received the drug registration certificate from the National Medical Products Administration for Crizotinib capsules, which have been on the Chinese market since 2013 and included in medical insurance since 2018, demonstrating over ten years of clinical application experience [1] Group 1 - Crizotinib capsules are primarily used for treating patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and ROS1-positive advanced NSCLC [1] - As a first-line treatment option, Crizotinib capsules provide over seven years of overall survival benefits for patients with advanced ALK/ROS1-positive NSCLC [1] - Crizotinib is the world's first targeted drug for ALK and the first-generation ALK tyrosine kinase inhibitor (ALK-TKI), targeting ALK and ROS1 to inhibit tumor cell proliferation and survival through a multi-target mechanism [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug registration certificate of Crizotinib capsules, indicating a significant advancement in its product portfolio [1] Group 1: Product Approval - The product Crizotinib capsules are primarily used for the treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients [1] - Crizotinib is also indicated for ROS1-positive advanced non-small cell lung cancer (NSCLC) patients [1]